FDA and CMS: A Path for Parallel Approvals for Innovative Technologies
01 April 2012
Partner Judith Waltz authored an article that appeared in Medical Design on April 1, 2012 titled “FDA and CMS: A path for parallel approvals for innovative technologies.”
Click here to read the complete article.
Click here to read the complete article.
Author(s)
Related Insights
12 December 2024
Energy Current
IRS Releases Final Regulations Under Section 48 of the Code
The Internal Revenue Service and Department of the Treasury last week released final regulations relating to investment tax credits under Section 48 of the of the Internal Revenue Code.
13 December 2024
Events
Korean Startups & Entrepreneurs: Innovation Weekend
Join Foley & Lardner, the host and sponsor, on December 13th for Day 1 of the KSE Innovation Weekend, dedicated to empowering founders and aspiring entrepreneurs.
08 January 2025
Events
Whistleblower Protections: Navigating Health Care Employment & Labor Rights
Events in our recent history — the COVID-19 pandemic, increase in financial incentives for whistleblowers, and expansion of laws providing whistleblower procedures — have resulted in a spike in the number of whistleblower complaints received by regulators and employers globally.